Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.
Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos transforms clinical practice by establishing the first FDA-approved standard of care for recurrent respiratory papillomatosis (RRP), shifting treatment from repeated surgeries to an immunotherapy that addresses the root HPV infection, with future plans to expand into pediatric populations and redosing strategies.
Pharmaceutical Executive Daily highlights major industry shifts, including job cuts at Lundbeck and Novo Nordisk, and Trump's critique of drug advertising practices.
White House plans potential restrictions on Chinese-developed drugs, sparking lobbying from investors and pharmaceutical giants amid national security concerns.
Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for treating primary biliary cholangitis.
Merck withdraws from its London research facility, highlighting growing concerns over the UK's life sciences investment climate and industry competitiveness.
Helen Sabzevari, PhD, president and CEO of Precigen, reflects on how Papzimeos sets an important precedent for rare disease therapies, with its broad FDA label for all adult patients with recurrent respiratory papillomatosis (RRP) highlighting the potential for earlier intervention to prevent irreversible damage and establish new standards of care.
Helen Sabzevari, PhD, president and CEO of Precigen, discusses the FDA’s decision to grant full approval to Papzimeos without requiring a confirmatory trial, highlighting how strong safety, efficacy, and durability data supported a broad label for all adult patients with recurrent respiratory papillomatosis (RRP).
Discover key strategies for enhancing pharmaceutical sales, the impact of AI in training, and FDA updates on GLP-1 compounding regulations.
Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.
Novartis acquires Tourmaline Bio to enhance its cardiovascular pipeline with Pacibekitug, a promising anti-inflammatory therapy for ASCVD.
In this video interview, Helen Sabzevari, PhD, president and CEO of Precigen, discusses the background of Recurrent Respiratory Papillomatosis treatments that led to Papzimeos becoming the first FDA-approved therapy for Recurrent Respiratory Papillomatosis.
In today’s Pharmaceutical Executive Daily, we review the wave of pharmaceutical layoffs shaping 2025, highlight the latest Pharm Exec Top 50 company rankings, and cover BioNTech and Duality Biologics’ clinical trial success with BNT323.
Regeneron’s Phase III trials show promising results for new antibody treatments, offering rapid and lasting relief from cat and birch allergies.
Servier's acquisition of KER-0193 marks a pivotal step in developing innovative treatments for Fragile X syndrome, enhancing its neurology pipeline.
Gilead Sciences partners with PEPFAR to enhance access to Lenacapavir for HIV prevention, aiming to support over 2 million people in resource-limited countries.
BioNTech's BNT323 shows promise in slowing breast cancer progression, boosting shares and paving the way for new treatment options.
In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.
Radiance Biopharma partners with Novatim to advance RB-601, a promising bispecific nanobody ADC targeting key cancer drivers for solid tumors.
In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.
Sanofi's stock plummets over 10% as Amlitelimab's Phase III trial results raise concerns about the company's future pipeline and Dupixent's patent expiration.
SeqOne's acquisition of Congenica enhances its AI-driven genomic solutions, expanding global reach and transforming genetic data analysis for personalized medicine.
Novo Nordisk reveals Wegovy's 57% greater risk reduction for heart attack and stroke compared to Tirzepatide in obese patients at ESC Congress.
Pharmaceutical Executive Daily highlights Pfizer's defense of vaccine data integrity, insights on GLP-1 investments, and Novartis' $5.2 billion acquisition of Argo Biopharmaceuticals.
Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using War-Lock technology, enhancing treatment options.
Argo Biopharmaceuticals partners with Novartis to advance innovative siRNA therapies for cardiovascular diseases, enhancing treatment options and patient outcomes.
OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their unique OdyssION drug discovery platform.
FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and safety in care.
Johnson and Johnson halts Nipocalimab's development for rheumatoid arthritis after Phase 2a trial shows no significant benefits over existing therapies.
The blood purification technology is used for the treatment of severe treatment-refectory systematic lupus erythematosus (SLE).
Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.
